Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Jun 2011

Murphy Mark, Stordal Britta

Abstract excerpt

BACKGROUND: Platinum-based chemotherapy is the standard of care for ovarian cancer and non-small cell lung cancer (NSCLC). However, resistance to platinum agents invariably develops. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have great potential here as they exert their anti-tumour effect via alternative mechanisms to platinum-based drugs and as such may remain unaffected by emergent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Resistance, Multiple

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Platinum

Share to Quinazolines

Source

Identifiers

PMID: 21435938
DOI: 10.1016/j.drup.2011.02.004

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.PMID 21435938Read ↗

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.Semantic proximity Read ↗

Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.Semantic proximity Read ↗

Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.Semantic proximity Read ↗

Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.Semantic proximity Read ↗

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.Semantic proximity Read ↗

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.Semantic proximity Read ↗

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.Semantic proximity Read ↗

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.Semantic proximity Read ↗

A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Safety, Tolerability, and Preliminary Efficacy AnalysisSemantic proximity Read ↗

[Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].Semantic proximity Read ↗

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.Semantic proximity Read ↗

Generation of Cisplatin-Resistant Ovarian Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.